How to use a parasite on its host, some tumors to protect themselves by taking non-cancer cells that normally help the immune system under control, say researchers at the Medical College of Georgia. When the researchers examined lymph nodes, where the tumor is usually the first shipment tumors are a subset of normal host immune cells express IDO, an enzyme expressed by the fetus immunosuppressants to prevent rejection by the immune system mother. They also found that if a drug used to block the expression of IDO as to recover the immune system.
Our hypothesis in this situation is that the really bad guys, in this case, the cells of normal cells of the landlord, who was in a sense, was requested by the tumor, says Dr. David Munn, hematologist pediatric oncologist and leadauthor of the study on the July 15 Journal of Clinical Investigation. Now they have shown in an animal model that these normal cells are a type of dendritic cells, which was previously ignored by scientists because they were the cells in the formation of antibodies involved in the suppression of the immune system believed.Recognizing the effective role of these cells previously discarded, the MCG scientists and their collaborators have devoted more to use this approach to help people with cancer.
We have shown that the IDO inhibitor drug is useful in mice, says Dr. Munn. E is useful in a tumor model that the type of patients we treat is bound. We can approach to approach the FDA suggests that inhibitors of IDO would be used in patients. The NIH study, the toxicity of theinhibitor of IDO and other studies necessary to meet the proposed clinical trials for the Food and Drug Administration, Dr.Munn said.
If the FDA clinical trials, is likely to be at least a year before starting his studies to look at the safety and efficacy of the treatments that help to make tumors more vulnerable to the immune system, Dr. Munn says. He added that the therapy would probably be a complement to existing
Pages:  2 3